Medication info

Linagliptin/Metformin Tablets 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Biconvex oval film-coated tablets of bright pink color
Packaging
For domestic use - 30 tablets/PTP [6 tablets/PTP x 5 packs]
Approval status
Expired

MFDS item code 202002371 · Approved 2020.04.04

This product's status changed to Expired on 2025.04.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current dose of metformin. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current dose of metformin. Patients with renal impairment Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes

View approved original text

This medication is taken in conjunction with dietary and exercise regimens to help control blood glucose levels in patients with type 2 diabetes using both linagliptin and metformin. It helps effectively manage blood glucose levels and alleviate symptoms of diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current dose of metformin. Patients who do not achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current dose of metformin. Patients with renal impairment Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months.

Precautions

This medication may rarely cause a serious side effect called lactic acidosis, so caution is necessary. Patients with allergies to any of the active ingredients or components of this drug, those with type 1 diabetes, those with lactic acidosis or diabetic ketoacidosis, and those with severe renal impairment should not take this medication. Additionally, it should be avoided in cases of acute illnesses such as dehydration, severe infections, myocardial infarction, and shock, as well as in patients with liver dysfunction. Women who are pregnant or breastfeeding are also advised not to use this medication. This medication may cause hypoglycemia, so blood glucose levels should be closely monitored, especially when taken with insulin or sulfonylureas. To reduce the risk of lactic acidosis, use this medication cautiously if blood glucose is poorly controlled or if there is excessive alcohol consumption, liver dysfunction, or cardiac conditions. If renal function is impaired, either avoid taking this medication or undergo regular kidney function tests; the elderly should also have their renal function periodically checked. If iodine contrast agents are used during radiological examinations, this medication should be discontinued for a certain period before and after the examination. It should also be discontinued for a certain period before and after surgery, and patients with heart failure should use it cautiously depending on their condition. If acute pancreatitis or suspected skin blistering disease occurs while taking this medication, it should be stopped immediately and the physician should be consulted. Long-term use may decrease vitamin B12 levels, so if anemia or neurological symptoms appear, vitamin B12 testing should be done. There may be interactions with other medications, so inform the doctor or pharmacist if you are taking other drugs. Women who are pregnant or planning to conceive should consider insulin therapy instead of this medication; nursing mothers should also avoid taking it. It is not recommended for children under 10 years of age as safety and efficacy have not been established. Elderly patients commonly have reduced renal function, so appropriate dosage adjustments and regular renal function testing are necessary. The effects on driving or operating machinery are not established, but caution is advised due to the risk of hypoglycemia. In case of overdose, there is a risk of lactic acidosis, so immediate medical treatment is required, and dialysis may be necessary.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, hypoglycemia, dysgeusia, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, bullous pemphigoid, arthralgia accompanied by severe pain and disability, rhabdomyolysis, increased lipase, increased amylase, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, gastrointestinal disorders, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer's disease, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, colorectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, confusion, nocturia, pruritus, hypertension, erectile dysfunction, goiter, decrease in hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine phosphokinase in the blood, male pattern baldness, hyperhidrosis, dermatitis, anxiety, insomnia, depression, angina, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, anal bleeding, cheilitis, cavities, enteritis, gastritis, stomatitis, dizziness, headache, drowsiness, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, rotator cuff syndrome, increased triglycerides in the blood, increased creatinine in the blood, increased creatine phosphokinase in the blood, increased triglycerides in the blood, pruritus, insomnia, depression, hypertension, dizziness, benign prostatic hyperplasia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air and moisture. Additionally, it is recommended to store it at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the efficacy and safety of the medication.

Appearance and packaging

Appearance

Biconvex oval film-coated tablets of bright pink color

Package unit

For domestic use - 30 tablets/PTP [6 tablets/PTP x 5 packs]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.